Pharma Times

DECEMBER 2, 2021

Researchers have identified in those patients experiencing blood clots after vaccination a subsequent condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT).

Vaccines 125

Vaccines Immunity Immunization 125

Pharma Times

JULY 28, 2021

No serious side effects were observed in the Phase I trial

Immunity 128

Immunity Immunization Vaccines 128

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccines 111

Vaccines Immunity Immunization 111

Pharma Times

DECEMBER 7, 2021

Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries.

Vaccines 113

Vaccines Immunity Immunization 113

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccines 119

Vaccines Immunity Immunization 119

pharmaphorum

NOVEMBER 25, 2021

The first patients are now being treated as part of a first-in-human trial of a vaccine, administered as a nasal spray, that aims to slow down the progression of Alzheimer’s disease (AD). Meanwhile researchers in Japan are also running preclinical studies of an intranasal tau vaccine.

Vaccines 98

Vaccines Immunity Immunization Hospitals 98

Pharma Times

JUNE 29, 2021

Mixing different vaccines produces a strong immune response against virus, according to researchers

Vaccines 127

Vaccines Immunity Immunization 127

pharmaphorum

MARCH 12, 2021

EU regulators are reviewing reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from Pfizer/BioNTech, AstraZeneca and Moderna. AZ vaccine safety update. The committee said appropriate medical treatment must be available in the event of an anaphylactic event with the vaccine.

Vaccines 145

Vaccines Labelling Immunity Immunization 145

Pharma Times

JULY 18, 2021

Studies showed immunosuppression appeared to weaken immune responses to COVID-19 vaccines

Vaccines 123

Vaccines Immunity Immunization 123

pharmaphorum

FEBRUARY 11, 2021

Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . The vaccine stimulated antibodies against the protein in all 32 patients with early-stage AD in the study at levels that AC Immune thinks should have a therapeutic effect.

Immunity 128

Immunity Immunization Vaccines 128

pharmaphorum

JULY 14, 2021

AstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk of severe blood clotting reactions that are seen – albeit rarely – in some people receiving the jabs. It suggests that AZ may be able to have a new version that sidesteps the clotting issue by next year.

Vaccines 116

Vaccines Immunity Immunization 116

pharmaphorum

SEPTEMBER 24, 2021

Targeting people for COVID-19 vaccination using contract-tracing apps could be a shortcut to achieving herd immunity in the population using fewer doses, according to Canadian researchers. It could reduce the number of vaccine doses needed to achieve herd immunity by up to one half, they calculate.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

MARCH 3, 2021

ISA hopes that ISA106 could be used in concert with a vaccination campaign, acting as a “safety net” in case more variant strains emerge or in people who are unwilling to take vaccines.

Immunity 105

Immunity Immunization Vaccines Hospitals 105

Pharma Times

MAY 14, 2021

Vaccine induced strong immune responses in a rat model during preclinical testing

Immunity 98

Immunity Immunization Vaccines 98

pharmaphorum

JULY 20, 2021

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. So far the EU has approved four COVID-19 vaccines – two mRNA shots from Pfizer/BioNTech and Moderna, and two based on adenoviral vectors from AstraZeneca and Johnson & Johnson.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

NOVEMBER 28, 2021

1.1.529 variant of COVID-19 – now christened Omicron – leading vaccine manufacturers have said they are poised to develop new shots if needed. Other vaccine manufacturers have also responded to the new variant. With governments around the world announcing measures to curb the new B.1.1.529

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

JANUARY 8, 2021

The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. The study team tested blood taken from people who had received the mRNA vaccine developed by BioNTech and Pfizer.

Vaccines 124

Vaccines Immunity Immunization 124

pharmaphorum

FEBRUARY 8, 2021

China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public. This is the second vaccine approved by China’s National Medical Products Administration (NMPA). Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme.

Vaccines 90

Vaccines Immunity Immunization 90

pharmaphorum

DECEMBER 8, 2021

A study by the African Health Research Institute (AHRI) has found that the less of immune protection was “extensive but incomplete,” meaning that some level of immunity was retained against the vaccine.

Vaccines 98

Vaccines Immunity Immunization Drug Development 98

pharmaphorum

JULY 26, 2021

Antibodies should be present in people who have previously exposed to the virus, or been vaccinated against it. The post Rapid COVID immune status test launched in UK, Ireland appeared first on. Another player is FlowMetric Life Sciences, which launched its quantitative diagnostic – VaxEffect – in the US two weeks ago.

Immunity 137

Immunity Immunization Vaccines 137

pharmaphorum

MAY 10, 2021

BioNTech has said it plans to set up a regional base and new manufacturing site in Singapore so that the biotech can keep pace with demand for its mRNA-based coronavirus vaccine and pipeline products in other disease areas. It’s an important milestone for the company, which established a US headquarters in Cambridge, Massachusetts last year.

Vaccines 129

Vaccines Immunity Immunization 129

pharmaphorum

MARCH 31, 2021

Germany and Canada have both slapped restrictions on the AstraZeneca vaccine, recommending its use only in older patients, because of concerns over a link with blood clots. According to STIKO the side effect occurred four to 16 days after vaccination and was predominantly seen in people under 60 years of age.

Vaccines 116

Vaccines Immunity Immunization 116

Pharma Times

MAY 17, 2021

Companies previously delayed vaccine programme after Phase I/II study results found a low immune response in older adults

Vaccines 72

Vaccines Immunity Immunization 72

pharmaphorum

FEBRUARY 18, 2021

The aim of the study is to find the smallest amount of SARS-CoV-2 that is needed to cause an infection, see how the immune system reacts to the virus, and to assist in the development of new treatments and vaccines. Dr Chris Chiu. Image by fernando zhiminaicela from Pixabay.

Vaccines 118

Vaccines Immunity Immunization 118

pharmaphorum

SEPTEMBER 8, 2021

The UK should think twice before backing widespread use of COVID-19 booster vaccinations, as to do so could place unnecessary burden on the NHS over the winter, according to AstraZeneca chief executive Pascal Soriot. It has already said that at-risk people, such as those with weakened immune systems, will be in line for a third dose.

Immunity 83

Immunity Immunization Vaccines Hospitals 83

pharmaphorum

JUNE 22, 2021

Sanofi and Translate Bio have started a first clinical trial of an mRNA-based seasonal flu vaccine, adding to the COVID-19 shot already in testing as part of their three-year old collaboration. Sanofi and Translate have been working together since 2018, when they agreed to develop mRNA vaccines for up to five infectious diseases.

Vaccines 114

Vaccines Immunity Immunization 114

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.

Vaccines 145

Vaccines Immunity Immunization 145

pharmaphorum

AUGUST 16, 2021

Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway. Mixing of the two mRNA vaccines is permitted for the third shot if the original vaccine received by a person is not available, according to the agency.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

MARCH 3, 2021

Novavax hopes its COVID-19 vaccine could be filed in the US in the second quarter, following a potential approval from the UK regulator in the coming weeks. Novavax’s vaccine is a sequence of protein engineered from the genetic sequence of the SARS-CoV-2 virus that mimics the “Spike” protein found on the pathogen’s surface.

Vaccines 130

Vaccines Immunity Immunization 130

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccines 95

Vaccines Immunity Immunization Compounding 95

pharmaphorum

APRIL 16, 2021

A study has suggested that the risk of getting a serious brain clot is eight to 10 times higher in people with COVID-19 than those who get a vaccine. The study follows investigations into potential links with the AstraZeneca vaccine and rare blood clots. But the researchers concluded they are still rarer after a vaccine.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

MAY 10, 2021

A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot. . It is also asking for similar data from Moderna, which manufacture a COVID-19 vaccine that like Comirnaty is based on mRNA.

Vaccines 122

Vaccines Labelling Immunity Immunization 122

pharmaphorum

MARCH 17, 2021

At the start of the pandemic GlaxoSmithKline made its vaccine booster tech available looking for collaborations with other vaccine developers – but GSK has been lagging behind rivals like Pfizer and AstraZeneca after its big tie-up with Sanofi hit technical troubles. micrograms of the vaccine are administered 21 days apart.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

JUNE 3, 2021

The UK government is talking to AstraZeneca about ordering additional doses of its COVID-19 vaccine that will target the beta variant of SARS-CoV-2 virus first identified in South Africa, according to Health Secretary Matt Hancock. 1.351 – which is estimated to be around 50% more transmissible than earlier strains.

Vaccines 113

Vaccines Immunity Immunization Hospitals 113

pharmaphorum

JULY 6, 2021

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The post Imugene HER2 vaccine hits target in stomach cancer trial appeared first on.

Vaccines 119

Vaccines Chemotherapy Immunity Immunization 119